An Open-label, Fixed-dose, Multicenter, Phase II Study of MDX-060 [iratumumab] in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Iratumumab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 27 Oct 2009 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 12 Jul 2007 Status changed from recruiting to completed.
- 08 Aug 2006 New trial record.